{"analyses":[{"ciLowerLimit":"0.55","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.74","estimateComment":"Stratified by Region and RPA Class.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"Stratified by Region and Recursive partitioning analysis (RPA) Class","paramType":"Hazard Ratio (HR)","paramValue":"0.64","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.0","upperLimit":"11.4","value":"10.6"},{"groupId":"OG001","lowerLimit":"6.0","upperLimit":"7.5","value":"6.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"458"},{"groupId":"OG001","value":"463"}],"units":"Participants"}],"description":"PFS is defined as time from randomization to disease progression (PD) or death. PD was assessed using adapted Macdonald response criteria (modified World Health Organization \\[WHO\\] criteria) based on 3 components: radiological tumor assessments using Magnetic Resonance Imaging \\[MRI\\] scans,neurological assessment and changes in corticosteroid use. PD is assessed as greater than or equal to(\\>=) 25% increase in sum of products of the longest diameters of all index lesions (enhancing,measurable) compared with the smallest recorded sum (nadir); or unequivocal PD of existing non-index lesions (non-enhancing and enhancing,non-measurable); or unequivocal appearance of new lesions); or neurological worsening (if corticosteroid dose is stable or increased) compared to neurological evaluation at previous disease assessment with no need for a confirmatory scan. Participants without a PFS event were censored at last disease assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"In the Concurrent Phase participants received radiotherapy (RT) in daily fractions of 2 Gray (Gy) given 5 days per weeks for 6 weeks (for a total of 60 Gy) and temozolomide 75 milligrams per square meter (mg/m\\^2) daily from the first day to the last day of radiotherapy (for a maximum of 49 days in case of delay to the end of radiation therapy) and bevacizumab (Avastin) 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of bevacizumab 10 mg/kg IV every 2 weeks and temozolomide 150 to 200 mg/m\\^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received bevacizumab 15 mg/kg IV every 3 weeks until disease progression/unacceptable toxicity. Participants then entered the last period: After Primary Overall Survival Analysis, in which participants were followed up for safety.","id":"OG000","title":"Bevacizumab + RT + Temozolomide"},{"description":"In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 weeks (for a total of 60 Gy) and temozolomide 75 mg/m\\^2 daily from the first day to the last day of radiotherapy (for a maximum of 49 days in case of delay to the end of radiation therapy) and placebo IV every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of placebo IV every 2 weeks and temozolomide 150 to 200 mg/m\\^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received placebo IV every 3 weeks until disease progression/unacceptable toxicity. Participants then entered the last period: After Primary Overall Survival Analysis, in which participants were followed up for safety.","id":"OG001","title":"Placebo + RT + Temozolomide"}],"paramType":"MEDIAN","populationDescription":"Intent to treat population.","reportingStatus":"POSTED","timeFrame":"Randomization until PFS Event [Until data cutoff= 31 March 2012 (up to 31.4 months)","title":"Co-Primary: Progression-free Survival (PFS) as Assessed by Investigator","type":"PRIMARY","unitOfMeasure":"Months"}